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Background: Previous studies have suggested that the variability in age of onset and
aggressiveness of medullary thyroid carcinoma (MTC) in patients with multiple endocrine
neoplasia type 2A (MEN 2A) carrying the same REarranged during Transfection (RET )
mutation may be caused by additional RET germline variants or somatic variants.
Methods: This study was a retrospective case comparison study of all MEN 2A index
patients (n = 2) with the RET L790F germline mutation in Denmark. Whole blood
and MTC tissue were analyzed for RET germline variants and other somatic variants
(>500), respectively.
Results: Patient 1 presented with MTC (T1aN1bM0) at age 14 years, while patient 2
presented with MTC (T1bN0M0) at age 70 years. No germline RET germline variants nor
other variants were found to explain this MTC variability.
Conclusions: We could not confirm the previously reported finding of a somatic RET
variant as likely responsible for the early onset and aggressiveness of MTC in a RET
germline mutation carrier. Also, we found no RET germline variants that could explain
the MTC variability among our index patients. We did, however, identify a somatic FLT3
R387Q variant with an unknown potential as genetic modifier. Further large-scale studies
are needed to investigate genetic modifiers in RET L790F carriers.
Keywords: multiple endocrine neoplasia type 2, medullary thyroid carcinoma, REarranged during Transfection,
L790F, variability, gene variants, FLT3 R387Q
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INTRODUCTION
Multiple endocrine neoplasia (MEN) 2 is an autosomal
dominant inherited cancer syndrome subdivided into MEN
2A and MEN 2B (1, 2). With a point prevalence of
13–24 and 1–2 per million, MEN 2A and MEN 2B are
rare (3–6). The syndromes, however, are accompanied by
major implications as virtually all patients develop medullary
thyroid carcinoma (MTC) while variable proportions develop
pheochromocytoma, primary hyperparathyroidism, cutaneous
lichen amyloidosis, Hirschsprung disease, ganglioneuromatosis
of the aerodigestive tract, facial, ophthalmologic, and skeletal
abnormalities (1).
MEN 2A and 2B are caused by germline mutations of
the REarranged during Transfection (RET) proto-oncogene
(7–11). Despite the recognition of strong genotype-phenotype
correlations (12, 13), several studies have observed a substantial
inter- and intra-familial variability in the age of onset and
aggressiveness of MTC among carriers of the same mutation
(14–21). Some authors have suggested that certain RET germline
variants (IVS1-126G>T, IVS8+82A>G; 85-86 insC, G691S,
L769L, S836S, S904S) in combination with a RET germline
mutation may modify the age of onset and aggressiveness
of MTC in MEN 2 patients (22–26). The issue, however, is
controversial (25–30). Others have suggested that the variability
may be caused by a somatic variant acting as the “second hit”
in Knudson’s two hit model (16, 31, 32). To our knowledge, no
such studies exist for MEN 2A patients carrying the RET L790F
germline mutation.
Consequently, we conducted the first study of RET germline
variants and somatic variants in L790F carriers, aiming to explain
the MTC variability among index patients in Denmark.
METHODS
Study Design and Participants
This investigation is a retrospective case study of all MEN 2A
index patients (n = 2) with the RET L790F germline mutation
in Denmark.
Data Sources
Patients were identified from the extended nationwide Danish
RET cohort 1994–2017 (33, 34), and data were drawn from the
Danish MEN 2A cohort 1901–2014, the Danish MTC cohort
1997–2014, and medical records (4, 35).
Genetic Testing
Testing for RET germline variants were performed using
Next Generation Sequencing as previously described (33).
Formalin-fixed paraffin-embedded tumoir tissue from MTC
primary tumor and metastases were tested for somatic RET
variants as reported earlier (36). Testing for somatic variants
in oncogenes was done by targeted exome sequencing; In
short, genomic DNA (200 ng) was fragmented to 300 bp
adaptor ligation using KAPA HTP Library Preparation Kit
(Roche) and enrichment of exome using SureSelectXT Clinical
Research Exome kit (Agilent). Paired-end sequencing (2 ×
100 or 2 × 150 bp) was performed to gain an average
coverage of 50–100× using the NextSeq500 platforms (Illumina).
Raw sequencing data were processed using CASAVA-1.8.2
and reads were aligned to the human reference genome
(hg19/GRCh37) using CLC Biomedical Genomics Workbench
(Qiagen). Variant calling >5% frequency and filtering for 523
cancer relevant genes, including RET, H-RAS, K-RAS, and N-
RAS using Ingenuity Variant Analysis (Qiagen). For this study,
“mutation” denotes a disease-causing (pathogenic) sequence
change, while “variant” denotes any sequence change, whether
pathogenic or not.
The investigation was approved by the Danish Health
Authority (3-3013-395/3) and the Danish Data Protection
Agency (18/17801). The Regional Committees on Health
Research Ethics for Southern Denmark found further review
was not liable to notification. Informed consent was obtained
from the cases for the publication of any potentially identifiable
images or data included in this article. The data that support the




A 14-year-old female of Lebanese origin, presented with
B-symptoms and multiple enlarged lymph nodes on the right
side of the neck. Fine-needle aspiration suggested plasma cells
or cells with thyroid or paraganglioma origin. A lymph node
biopsy was taken and histology showed MTC metastasis. After
this, basal calcitonin was measured to 18.3 µg/L (<0.1 µg/L).
The patient underwent a total thyroidectomy and right-sided
neck dissection. Histology displayed multifocal MTC (largest
tumor 7mm) with metastases to 17 of 20 removed lymph
nodes and a normal parathyroid gland. The final TNM-stage
was T1aN1bM0. Two months postoperatively basal calcitonin
was 19.0 µg/L (<0.1 µg/L) and adjuvant radiotherapy was
given. RET testing revealed the L790F (c.2370G>T) germline
mutation. There was no family history of MEN 2A. The father
was tested negative for RET mutations, while the mother was
positive for the L790F mutation. The latter, however, declined
further work up. Fourteen years later basal calcitonin had
risen to 59,280 ng/L (<7.3 ng/L). Distant metastases were
cytologically verified in mediastinal lymph nodes and suspected
in the neck, lungs, mamma, liver, and in proximity to the
transverse colon. The patient was initiated on Vandetanib, a
tyrosine kinase inhibitor. Thirty months after initiation, the
patient had basal calcitonin of 80 ng/L and apart from the
suspected liver metastasis that was assessed without change
there were no radiological evidence of metastases on CT scan.
Neither pheochromocytoma nor primary hyperparathyroidism
has been diagnosed during the 16 years of follow-up. Table 1
shows clinical characteristics and results of genetic analyses
for patient 1.
Patient 2
A 70-year-old female, presented with a right-sided thyroid tumor,
but was otherwise asymptomatic. Fine-needle aspiration showed
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TABLE 1 | Clinical and genetic characteristics of two index patients with the RET
L790F germline mutation.
Patient 1 Patient 2
Sex Female Female
Ethnic origin Lebanese Danish
MTC at diagnosis
Age, years 14 70





IVS1-126G>T (rs2565206) – –
A45A (rs1800858) + +
c.337+9G>A (rs2435351) + +
IVS4+48A>G (rs2435352) + +
IVS8+82A>G; 85–86 insC (rs3026750; rs3482797) – –
A432A (rs1800860) – +
G691S (rs1799939) – +
IVS12+47C>T (rs760466) + –
L769L (rs1800861) + +
L790F (rs75030001) + +
S836S (rs1800862) – –
S904S (rs1800863) – +
IVS19+47C>T (rs2075912) + +
Somatic variants
RET – –
N-RAS, K-RAS, or H-RAS – –
FLT3 (R387Q) (rs751562024) + –
Other genes analyzed (>500)a – –
MTC, medullary thyroid carcinoma; RET, REarranged during Transfection.
aList of genes analyzed can be found in Appendix 1.
follicular neoplasm of unknown malignant potential. The
medical history was unremarkable apart from a right-sided
ductal carcinoma in situ treated with lumpectomy and
radiotherapy 18 months earlier. The patient underwent a
left-sided hemithyroidectomy without prior measurement of
serum calcitonin, as MTC was unsuspected. Histology revealed
multifocal MTC with the largest tumor size of 15mm. At
this point, basal serum calcitonin was 28 ng/L (<7.3 ng/L)
and family history revealed that the mother and aunt had
undergone thyroid operations for unknown causes. The
patient underwent right-sided completion thyroidectomy.
Histology showed multifocal MTC with several tumors
measuring 1–3mm. Also, a removed lymph node was without
metastasis. The final TNM-stage was T1bN0M0. A RET
test identified the L790F (c.2370G>T) germline mutation.
Subsequently, normal tissue from the deceased mother was
also tested positive for the L790F mutation. Basal serum
calcitonin was immeasurable and no biochemical signs of
pheochromocytoma or primary hyperparathyroidism have
been present after 1 year of follow-up. Clinical characteristics
and results of genetic analyses for patient 2 can be seen
in Table 1.
Genetic Characteristics
The only RET germline variant and the only somatic variant
exclusively identified in patient 1 were IVS12+47C>T and FLT3
R387Q (c.1160G>A), respectively. The RET variants exclusively
found in patient 2 were A432A, G691S, and S904S.
DISCUSSION
Despite thorough investigations, this study found no RET
germline variants or other somatic variants that could
convincingly explain the substantial variability in MTC
phenotype seen in our two L790F index patients.
Patient 1 presented with MTC and lymph node metastases
at 14 years old, several years earlier than the reported median
age (57 years) for MTC presentation in L790F index patients
(37). The only RET germline variant exclusively identified in this
patient was IVS12+47C>T. While other RET intron variants
(IVS1-126G>T, IVS8+82A>G; 85-86 insC) have been associated
to earlier age at MTC onset and the presence of lymph node
metastases at diagnosis (26), no similar association has been
reported for the RET IVS12+47C>T variant. The variant is
classified as benign in the ClinVar database according to the
criteria from the American College of Medical Genetics and
Genomics (38, 39). To the best of our knowledge, no functional
studies of this variant exist.
The only somatic variant exclusively found in patient
1 was FLT3 R387Q (c.1160G>A). Fms-like tyrosine kinase
3 ligand (FL) is the cytokine ligand of FLT3, which is
considered an important growth and differentiation factor. FLT3
is commonly found in hematopoietic malignancies. In most
cases, this is due to activating mutations in the FLT3 gene
but a significant number of leukemias are also characterized
by a higher than normal expression level of un-mutated,
wild-type FLT3, thus emphasizing the importance of FLT3
signaling perturbations inmalignant transformation. FL interacts
with FLT3 at the EF-loop of the homodimeric FLT3. R387
is situated in the D4 domain of FLT3 interacting with FL
(Figure 1) and is part of the interface of D4 taking part
in homodimerization. R387 is part of the FG-loop situated
next to the highly conserved EF-loop constituting the tyrosine
corner. In the majority of other tyrosine kinase receptors the
homodimerization is achieved by hydrogen bonds between
argenines and glutamines of the FG-Loop. FLT3 show sequence
dissimilarity in this particular region of the D4 domain region
to other tyrosine kinase receptors. It can be hypothesized that
R387Q could be part of a hydrogen binding motif with the
opposing Glutamine 365 or 366 in the FLT3 partner. Thus,
we cannot exclude a possible genetic modifying role for the
R387Q variant.
Patient 2 presented relatively late with an intrathyroidal
MTC at 70 years old. Variants exclusively found in this patient
were A432A, G691S, and S904S. Of these variants, the G691S
and S904S variant and their association to MTC have been
investigated in several MEN 2A studies (22, 23, 25–27, 29).
A study of 104 MEN 2A patients from Spain suggested that
G691S and S904S could be related to early appearance of
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FIGURE 1 | FLT3: FL interaction. D4 interface taking part in FL binding shown
in marine blue. Conserved disulfid bridges of the FLT3 Homotype interacting
D4 domains in yellow. The highly conserved Tyrosin of the EF-Loop is shown in
red. D5 domains in orange. The variation R387 in magenta. Glutamines
opposing R387 involved in homodimerisation shown in light grey. The upper
part of the figure (in raspberry) represents part of the D1, D2 and D3 domains.
symptoms in an overall MEN 2A group and in a group with
codon 634 mutations only (22). Similarly, a recent Italian study
observed an earlier age at MTC diagnosis in patients carrying
the G691S variant and the S891A germline mutation compared
to those only carrying the S891A mutation (23). However, in
the present study, we could not confirm a genetic modifier
effect of the G691S and S904S variant when comparing our
two L790F index patients. This is in accordance with other
investigations that studied the G691S and S904S variant in MEN
2A patients carrying mutations of codon 533, 618, and 634
(25–27, 29).
The last variant exclusively found in patient 2 was A432A. An
international collaborative study of 384 MEN 2A patients from
four different European populations suggested a protective effect
of the A432A variant with a 50% decreased risk of developing
pheochromocytoma and/or primary hyperparathyroidism
(P = 0.03) (27). Such an effect cannot be ruled out for
patient 2, as she has not presented with other MEN 2A
manifestations despite a relatively advanced age at MTC
diagnosis. However, the penetrance of pheochromocytoma
and primary hyperparathyroidism in L790F carriers has been
reported as exceedingly low (20). Although pheochromocytoma
often is reported in carriers of codon 634 mutations (40–45),
there have also been reports of this manifestation in L790F
carriers (20, 46–48). Opposed to the phenotype of our two
patients, having only MTC and no pheochromocytoma, a
44-year-old L790F carrier has been reported to present with
bilateral pheochromocytoma and no evidence of MTC. The
report underlines the need for MEN 2 screening in all patients
with pheochromocytoma and the need for lifelong screening for
pheochromocytoma in all MEN 2 patients (46, 49).
We found no somatic variants in RET, H-RAS, K-RAS,
and N-RAS in neither of our MEN 2A index patients. This
is consistent with some studies (50–53), but in contrast to
others (54, 55). None of these studies correlated the absence
or presence of somatic variants to the age at diagnosis
and aggressiveness of MTC. This was, however, done in a
French-Italian collaborative study of V804L carriers (16). Despite
V804L carriers usually displaying a late onset and an indolent
course of C-cell disease, the authors reported of an index
patient, who presented with a thyroid tumor (25mm), clinical
lymph node involvement, and elevated basal calcitonin (1,750
pg/ml) at 12 years of age. A somatic M918T mutation was
detected in the patient’s tumor. The authors hypothesized
that the two mutations were likely responsible for both the
early clinical onset and the aggressiveness of the tumor (16).
The lack of somatic RET variants in both our index patients
suggests that a similar hypothesis may not be valid for L790F
carriers. However, future large-scale studies are needed to
adequately address the question. Such studies are also needed
to provide more information of useful genotype-phenotype
correlations for better prognostication in L790 carries. The
present investigation is limited by the lack of functional
studies although they can be misleading from time to other
(36, 56).
As patient 1 was of Lebanese origin (immigrated to
Denmark at four years of age) and patient 2 of Danish
origin, influence of ethnic, and geographical factors cannot be
completely ruled out. Even though other studies have found
geographical differences in pheochromocytoma of MEN 2A and
survival of MEN 2B patients, the issue remains hypothetical
(57, 58).
CONCLUSIONS
We could not confirm the previously reported finding of a
somatic RET variant as likely responsible for the early onset
and aggressiveness of MTC in a RET germline mutation
carrier. Also, we found no RET germline variants that could
explain the MTC variability among our index patients. We
did, however, identify a somatic FLT3 R387Q variant with
an unknown potential as genetic modifier. Further large-scale
studies are needed to investigate genetic modifiers in RET
L790F carriers.
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